This trial is active, not recruiting.

Condition colo-rectal cancer
Treatment liver transplantation and colo-rectal cancer
Phase phase 2
Sponsor Oslo University Hospital
Start date February 2006
End date May 2022
Trial size 25 participants
Trial identifier NCT00294827, S-05409 (SECA I)


Survival of colo-rectal cancer patients after liver transplantation.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
liver transplantation and colo-rectal cancer
Liver transplantation

Primary Outcomes

time frame: 6 years

Secondary Outcomes

Time to progression side-effects
time frame: 6 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria:Colo-rectal cancer - Exclusion Criteria:

Additional Information

Official title Liver Transplantation and Metastatic Colo-rectal Cancer.
Principal investigator Svein Dueland, MD, PhD
Description Survival, time to progression, other malignancy, side-effects, quality of life.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Oslo University Hospital.